Moderna, Inc.今日盘中大涨5.13%，引起了市场的广泛关注。
消息面上，公司季节性流感疫苗候选产品mRNA-1010此前获得美国食品药品监督管理局咨询委员会的一致支持，市场对其最终获批的预期持续升温。此外，Arete于近期将公司目标价大幅上调至433美元，远超市场一致预期。
公司在其科学日活动上首次披露了针对自身免疫疾病的体内CAR-T项目mRNA-6007，并计划于明年进入临床阶段。同时，公司展示了包括肿瘤疫苗和AI研发平台在内的多条管线进展，市场对其向平台型生物药企进行估值切换的预期正在持续发酵。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.